TW201838631A - 作為ros1激酶抑制劑的巨環化合物 - Google Patents

Info

Publication number

TW201838631A

TW201838631A TW107109131A TW107109131A TW201838631A TW 201838631 A TW201838631 A TW 201838631A TW 107109131 A TW107109131 A TW 107109131A TW 107109131 A TW107109131 A TW 107109131A TW 201838631 A TW201838631 A TW 201838631A

Authority

TW

Taiwan

Prior art keywords

alkyl

ros1

cancer

ring

individual

Prior art date

2017-03-16

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003757 phosphotransferase inhibitor Substances 0.000 title description 40
• 229940043355 kinase inhibitor Drugs 0.000 title description 39
• 150000002678 macrocyclic compounds Chemical class 0.000 title description 3
• 101100091501 Mus musculus Ros1 gene Proteins 0.000 title 1
• 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims abstract description 668
• 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims abstract description 667
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 521
• 201000011510 cancer Diseases 0.000 claims abstract description 406
• 238000000034 method Methods 0.000 claims abstract description 305
• 150000001875 compounds Chemical class 0.000 claims abstract description 260
• 150000003839 salts Chemical class 0.000 claims abstract description 178
• 238000011282 treatment Methods 0.000 claims abstract description 102
• 125000000217 alkyl group Chemical group 0.000 claims description 553
• 239000003112 inhibitor Substances 0.000 claims description 339
• 230000035772 mutation Effects 0.000 claims description 236
• 239000012453 solvate Substances 0.000 claims description 162
• 210000004027 cell Anatomy 0.000 claims description 150
• 230000000694 effects Effects 0.000 claims description 147
• 101150035397 Ros1 gene Proteins 0.000 claims description 138
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 135
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 109
• 229910052736 halogen Inorganic materials 0.000 claims description 93
• 150000002367 halogens Chemical class 0.000 claims description 93
• 229910052739 hydrogen Inorganic materials 0.000 claims description 77
• 238000004458 analytical method Methods 0.000 claims description 76
• 230000014509 gene expression Effects 0.000 claims description 75
• 229910052731 fluorine Inorganic materials 0.000 claims description 73
• 229910052799 carbon Inorganic materials 0.000 claims description 67
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 65
• 125000003545 alkoxy group Chemical group 0.000 claims description 65
• 239000003814 drug Substances 0.000 claims description 54
• -1 FIG Proteins 0.000 claims description 51
• 239000002246 antineoplastic agent Substances 0.000 claims description 50
• 125000001153 fluoro group Chemical group F* 0.000 claims description 49
• PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 46
• 238000009097 single-agent therapy Methods 0.000 claims description 41
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
• 229940124597 therapeutic agent Drugs 0.000 claims description 35
• 230000004927 fusion Effects 0.000 claims description 34
• 125000004429 atom Chemical group 0.000 claims description 32
• 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 30
• 230000001965 increasing effect Effects 0.000 claims description 30
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
• 238000002560 therapeutic procedure Methods 0.000 claims description 29
• 230000005764 inhibitory process Effects 0.000 claims description 22
• 229910052760 oxygen Inorganic materials 0.000 claims description 21
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
• 229910052757 nitrogen Inorganic materials 0.000 claims description 19
• 125000005842 heteroatom Chemical group 0.000 claims description 18
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 15
• LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical group N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims description 15
• 238000006467 substitution reaction Methods 0.000 claims description 12
• 102000004190 Enzymes Human genes 0.000 claims description 11
• 108090000790 Enzymes Proteins 0.000 claims description 11
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
• 239000003795 chemical substances by application Substances 0.000 claims description 11
• 238000001574 biopsy Methods 0.000 claims description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 238000007481 next generation sequencing Methods 0.000 claims description 10
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
• 206010009944 Colon cancer Diseases 0.000 claims description 8
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
• 229940127089 cytotoxic agent Drugs 0.000 claims description 8
• 230000009977 dual effect Effects 0.000 claims description 8
• 238000003364 immunohistochemistry Methods 0.000 claims description 8
• 239000003547 immunosorbent Substances 0.000 claims description 8
• 238000007901 in situ hybridization Methods 0.000 claims description 8
• 201000005202 lung cancer Diseases 0.000 claims description 8
• 208000020816 lung neoplasm Diseases 0.000 claims description 8
• 238000012175 pyrosequencing Methods 0.000 claims description 8
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
• 238000002626 targeted therapy Methods 0.000 claims description 8
• 125000001072 heteroaryl group Chemical group 0.000 claims description 7
• 206010004593 Bile duct cancer Diseases 0.000 claims description 6
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
• 238000001959 radiotherapy Methods 0.000 claims description 6
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
• 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
• 239000011737 fluorine Substances 0.000 claims description 5
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
• 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 230000019491 signal transduction Effects 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 208000009956 adenocarcinoma Diseases 0.000 claims description 3
• 231100000433 cytotoxic Toxicity 0.000 claims description 3
• 230000001472 cytotoxic effect Effects 0.000 claims description 3
• 208000005017 glioblastoma Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 210000000651 myofibroblast Anatomy 0.000 claims description 3
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 206010010356 Congenital anomaly Diseases 0.000 claims description 2
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
• 101000740519 Homo sapiens Syndecan-4 Proteins 0.000 claims description 2
• 108091006576 SLC34A2 Proteins 0.000 claims description 2
• 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims description 2
• 102100037220 Syndecan-4 Human genes 0.000 claims description 2
• 150000001335 aliphatic alkanes Chemical group 0.000 claims description 2
• 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
• 206010073373 small intestine adenocarcinoma Diseases 0.000 claims description 2
• 201000011531 vascular cancer Diseases 0.000 claims description 2
• 125000002252 acyl group Chemical group 0.000 claims 14
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 14
• 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 claims 12
• 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims 11
• 102100036675 Golgi-associated PDZ and coiled-coil motif-containing protein Human genes 0.000 claims 2
• 238000012163 sequencing technique Methods 0.000 claims 2
• 230000001568 sexual effect Effects 0.000 claims 2
• QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 claims 1
• 102100025007 14-3-3 protein epsilon Human genes 0.000 claims 1
• 208000003950 B-cell lymphoma Diseases 0.000 claims 1
• 102100028737 CAP-Gly domain-containing linker protein 1 Human genes 0.000 claims 1
• 102100035444 Centrosomal protein of 85 kDa-like Human genes 0.000 claims 1
• 102100026127 Clathrin heavy chain 1 Human genes 0.000 claims 1
• 102100032410 Coiled-coil domain-containing protein 30 Human genes 0.000 claims 1
• 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 claims 1
• 102100039368 ER lumen protein-retaining receptor 2 Human genes 0.000 claims 1
• 102100020903 Ezrin Human genes 0.000 claims 1
• 101710102980 Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 claims 1
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
• 108010075704 HLA-A Antigens Proteins 0.000 claims 1
• 102100030332 Homeobox protein Mohawk Human genes 0.000 claims 1
• 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 claims 1
• 101000767052 Homo sapiens CAP-Gly domain-containing linker protein 1 Proteins 0.000 claims 1
• 101000737643 Homo sapiens Centrosomal protein of 85 kDa-like Proteins 0.000 claims 1
• 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 claims 1
• 101000868780 Homo sapiens Coiled-coil domain-containing protein 30 Proteins 0.000 claims 1
• 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 claims 1
• 101000812465 Homo sapiens ER lumen protein-retaining receptor 2 Proteins 0.000 claims 1
• 101000854648 Homo sapiens Ezrin Proteins 0.000 claims 1
• 101001072499 Homo sapiens Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 claims 1
• 101000990997 Homo sapiens Homeobox protein Mohawk Proteins 0.000 claims 1
• 101001134694 Homo sapiens LIM domain and actin-binding protein 1 Proteins 0.000 claims 1
• 101001017855 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 3 Proteins 0.000 claims 1
• 101001064542 Homo sapiens Liprin-beta-1 Proteins 0.000 claims 1
• 101000987094 Homo sapiens Moesin Proteins 0.000 claims 1
• 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 claims 1
• 101000586632 Homo sapiens PWWP domain-containing protein 2A Proteins 0.000 claims 1
• 101000800847 Homo sapiens Protein TFG Proteins 0.000 claims 1
• 101000703745 Homo sapiens Shootin-1 Proteins 0.000 claims 1
• 101000834926 Homo sapiens Transmembrane protein 106B Proteins 0.000 claims 1
• 101000610794 Homo sapiens Tumor protein D53 Proteins 0.000 claims 1
• 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 claims 1
• 101000788847 Homo sapiens Zinc finger CCHC domain-containing protein 8 Proteins 0.000 claims 1
• 102100033339 LIM domain and actin-binding protein 1 Human genes 0.000 claims 1
• 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 claims 1
• 102100031961 Liprin-beta-1 Human genes 0.000 claims 1
• 102100027869 Moesin Human genes 0.000 claims 1
• 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 claims 1
• 102100029733 PWWP domain-containing protein 2A Human genes 0.000 claims 1
• 102100033661 Protein TFG Human genes 0.000 claims 1
• 102100031975 Shootin-1 Human genes 0.000 claims 1
• 102100026232 Transmembrane protein 106B Human genes 0.000 claims 1
• 102100040362 Tumor protein D53 Human genes 0.000 claims 1
• 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 claims 1
• 102100025400 Zinc finger CCHC domain-containing protein 8 Human genes 0.000 claims 1
• 230000006907 apoptotic process Effects 0.000 claims 1
• 210000004204 blood vessel Anatomy 0.000 claims 1
• 102220419466 c.15A>G Human genes 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 abstract description 13
• 208000035475 disorder Diseases 0.000 description 90
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 71
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 70
• 108090000623 proteins and genes Proteins 0.000 description 63
• 239000000523 sample Substances 0.000 description 49
• 201000010099 disease Diseases 0.000 description 39
• 108020001507 fusion proteins Proteins 0.000 description 39
• 102000037865 fusion proteins Human genes 0.000 description 39
• 238000011528 liquid biopsy Methods 0.000 description 36
• 102000004169 proteins and genes Human genes 0.000 description 31
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 30
• 230000037430 deletion Effects 0.000 description 29
• 238000012217 deletion Methods 0.000 description 29
• 108091000080 Phosphotransferase Proteins 0.000 description 27
• 102000020233 phosphotransferase Human genes 0.000 description 27
• 238000009169 immunotherapy Methods 0.000 description 26
• 101150111535 trk gene Proteins 0.000 description 21
• 101150023956 ALK gene Proteins 0.000 description 20
• 239000002585 base Substances 0.000 description 19
• 239000000203 mixture Substances 0.000 description 18
• 239000013589 supplement Substances 0.000 description 18
• 229960005061 crizotinib Drugs 0.000 description 17
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 17
• 238000001514 detection method Methods 0.000 description 17
• 238000003780 insertion Methods 0.000 description 17
• 230000037431 insertion Effects 0.000 description 17
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 16
• 206010027476 Metastases Diseases 0.000 description 16
• 230000001105 regulatory effect Effects 0.000 description 16
• 229960001602 ceritinib Drugs 0.000 description 14
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 14
• 230000009401 metastasis Effects 0.000 description 14
• 230000005945 translocation Effects 0.000 description 13
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
• 239000008194 pharmaceutical composition Substances 0.000 description 12
• 238000011160 research Methods 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• 108020004999 messenger RNA Proteins 0.000 description 10
• 125000001424 substituent group Chemical group 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• 125000004432 carbon atom Chemical group C* 0.000 description 9
• 150000001413 amino acids Chemical class 0.000 description 8
• 229940022399 cancer vaccine Drugs 0.000 description 8
• 238000009566 cancer vaccine Methods 0.000 description 8
• 229940127084 other anti-cancer agent Drugs 0.000 description 8
• 230000007170 pathology Effects 0.000 description 8
• 238000007363 ring formation reaction Methods 0.000 description 8
• 208000034951 Genetic Translocation Diseases 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000008482 dysregulation Effects 0.000 description 7
• 230000002489 hematologic effect Effects 0.000 description 7
• 208000032839 leukemia Diseases 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 241000282414 Homo sapiens Species 0.000 description 6
• 108010006519 Molecular Chaperones Proteins 0.000 description 6
• 102000005431 Molecular Chaperones Human genes 0.000 description 6
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
• 230000037011 constitutive activity Effects 0.000 description 6
• 125000001183 hydrocarbyl group Chemical group 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 150000007523 nucleic acids Chemical class 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
• LBVKEEFIPBQIMD-JTQLQIEISA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]-4-n-(3-propan-2-yloxy-1h-pyrazol-5-yl)pyrimidine-2,4-diamine Chemical compound N1C(OC(C)C)=CC(NC=2C(=CN=C(N[C@@H](C)C=3N=CC(F)=CC=3)N=2)Cl)=N1 LBVKEEFIPBQIMD-JTQLQIEISA-N 0.000 description 5
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 238000011319 anticancer therapy Methods 0.000 description 4
• 230000003305 autocrine Effects 0.000 description 4
• 229950002916 avelumab Drugs 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
• 238000001952 enzyme assay Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
• 229940124303 multikinase inhibitor Drugs 0.000 description 4
• 229960003301 nivolumab Drugs 0.000 description 4
• 229960002621 pembrolizumab Drugs 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 229960004641 rituximab Drugs 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 229960005486 vaccine Drugs 0.000 description 4
• AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 3
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• MGGBYMDAPCCKCT-UHFFFAOYSA-N ASP-3026 Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=NC=1NC1=CC=CC=C1S(=O)(=O)C(C)C MGGBYMDAPCCKCT-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000016718 Chromosome Inversion Diseases 0.000 description 3
• 229940021995 DNA vaccine Drugs 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 102000000588 Interleukin-2 Human genes 0.000 description 3
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 3
• 101150111783 NTRK1 gene Proteins 0.000 description 3
• 206010028767 Nasal sinus cancer Diseases 0.000 description 3
• 101150056950 Ntrk2 gene Proteins 0.000 description 3
• 108091005461 Nucleic proteins Proteins 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• 101710091952 Tropomyosin alpha-3 chain Proteins 0.000 description 3
• 108700025316 aldesleukin Proteins 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 229960001292 cabozantinib Drugs 0.000 description 3
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000002659 cell therapy Methods 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 229950009791 durvalumab Drugs 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 229960005386 ipilimumab Drugs 0.000 description 3
• 230000000366 juvenile effect Effects 0.000 description 3
• 238000012332 laboratory investigation Methods 0.000 description 3
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 229960001972 panitumumab Drugs 0.000 description 3
• 230000007918 pathogenicity Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 150000003254 radicals Chemical class 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 150000003512 tertiary amines Chemical class 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• 230000005740 tumor formation Effects 0.000 description 3
• NXNQLECPAXXYTR-LCYFTJDESA-N (3z)-3-[(1-methylindol-3-yl)methylidene]-1h-pyrrolo[3,2-b]pyridin-2-one Chemical compound C12=CC=CC=C2N(C)C=C1\C=C/1C2=NC=CC=C2NC\1=O NXNQLECPAXXYTR-LCYFTJDESA-N 0.000 description 2
• YYDUWLSETXNJJT-MTJSOVHGSA-N 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-methyl-3-[[(3z)-2-oxo-3-(1h-pyrrol-2-ylmethylidene)-1h-indol-6-yl]amino]phenyl]urea Chemical compound C1=C(NC=2C=C3NC(=O)C(=C\C=4NC=CC=4)/C3=CC=2)C(C)=CC=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1F YYDUWLSETXNJJT-MTJSOVHGSA-N 0.000 description 2
• ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 2
• WLAVZAAODLTUSW-UHFFFAOYSA-N 1-n'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=O)C4(CC4)C(=O)NC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 WLAVZAAODLTUSW-UHFFFAOYSA-N 0.000 description 2
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 2
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
• WSTUJEXAPHIEIM-UHFFFAOYSA-N 4-fluoro-n-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide Chemical compound C1CC(C(=O)NC(C)C)CCC1N(C=1C(=CC=C(CN2CCC(CC2)C(C)(C)O)C=1)N\1)C/1=N/C(=O)C1=CC=C(F)C=C1 WSTUJEXAPHIEIM-UHFFFAOYSA-N 0.000 description 2
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
• QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 2
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
• XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 238000011357 CAR T-cell therapy Methods 0.000 description 2
• 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
• 229940045513 CTLA4 antagonist Drugs 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102100031939 Erythropoietin Human genes 0.000 description 2
• 108010029961 Filgrastim Proteins 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 208000021309 Germ cell tumor Diseases 0.000 description 2
• 239000007821 HATU Substances 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000003812 Interleukin-15 Human genes 0.000 description 2
• 108090000172 Interleukin-15 Proteins 0.000 description 2
• 102000000704 Interleukin-7 Human genes 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 206010062038 Lip neoplasm Diseases 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 101150117329 NTRK3 gene Proteins 0.000 description 2
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 239000012271 PD-L1 inhibitor Substances 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 206010043515 Throat cancer Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
• 125000006241 alcohol protecting group Chemical group 0.000 description 2
• 229960005310 aldesleukin Drugs 0.000 description 2
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
• 150000008041 alkali metal carbonates Chemical class 0.000 description 2
• 125000006242 amine protecting group Chemical group 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 238000009175 antibody therapy Methods 0.000 description 2
• 229940049595 antibody-drug conjugate Drugs 0.000 description 2
• 238000011394 anticancer treatment Methods 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 229960003008 blinatumomab Drugs 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 230000000711 cancerogenic effect Effects 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 231100000315 carcinogenic Toxicity 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 108010017271 denileukin diftitox Proteins 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 2
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
• 210000002768 hair cell Anatomy 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 208000024348 heart neoplasm Diseases 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 2
• 201000008298 histiocytosis Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229940100994 interleukin-7 Drugs 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 230000000155 isotopic effect Effects 0.000 description 2
• 201000006721 lip cancer Diseases 0.000 description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
• 229950010895 midostaurin Drugs 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 2
• 208000025113 myeloid leukemia Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 2
• 229960000513 necitumumab Drugs 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 229960002450 ofatumumab Drugs 0.000 description 2
• 229950008516 olaratumab Drugs 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 244000309459 oncolytic virus Species 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 201000007052 paranasal sinus cancer Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
• 229940023041 peptide vaccine Drugs 0.000 description 2
• 208000028591 pheochromocytoma Diseases 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 229960002633 ramucirumab Drugs 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000037983 regulatory factors Human genes 0.000 description 2
• 108091008025 regulatory factors Proteins 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 2
• 102200104802 rs13406336 Human genes 0.000 description 2
• 229950010611 sitravatinib Drugs 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 108010078373 tisagenlecleucel Proteins 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 229960001612 trastuzumab emtansine Drugs 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• DWYRIWUZIJHQKQ-SANMLTNESA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1 DWYRIWUZIJHQKQ-SANMLTNESA-N 0.000 description 1
• LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 description 1
• JUTDHSGANMHVIC-SNVBAGLBSA-N (2r)-2-phenylpyrrolidine Chemical group C1CCN[C@H]1C1=CC=CC=C1 JUTDHSGANMHVIC-SNVBAGLBSA-N 0.000 description 1
• YYACLQUDUDXAPA-MRXNPFEDSA-N (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1[C@H](F)CCN1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC(=NC=2)C2CC2)=C1F YYACLQUDUDXAPA-MRXNPFEDSA-N 0.000 description 1
• NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
• SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• LCFFREMLXLZNHE-GBOLQPHISA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@@H]2CCCN(C2)C(=O)C(/C#N)=C/C(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-GBOLQPHISA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• QHLVBNKYJGBCQJ-UHFFFAOYSA-N 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(OC(F)(F)F)C(NC=2N=C3C=4N(CCO)N=C(C=4CCC3=CN=2)C(N)=O)=C1 QHLVBNKYJGBCQJ-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 1
• TXDIRJCYNAWBOS-UHFFFAOYSA-N 1-[4-[4-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(Cl)C=1NC(C(=C1)OC)=CC=C1N1CCN(C(C)=O)CC1 TXDIRJCYNAWBOS-UHFFFAOYSA-N 0.000 description 1
• BLGCSOKKBWHJMB-HHHXNRCGSA-N 1-[4-[6-[6-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]pyridin-2-yl]piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC(C=2N=C(C=CC=2)C=2N3N=C(C=CC3=NC=2)N2[C@H](CCC2)C=2C=C(F)C=CC=2)=CC=N1 BLGCSOKKBWHJMB-HHHXNRCGSA-N 0.000 description 1
• BLGCSOKKBWHJMB-UHFFFAOYSA-N 1-[4-[6-[6-[2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]pyridin-2-yl]piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC(C=2N=C(C=CC=2)C=2N3N=C(C=CC3=NC=2)N2C(CCC2)C=2C=C(F)C=CC=2)=CC=N1 BLGCSOKKBWHJMB-UHFFFAOYSA-N 0.000 description 1
• JWVTWJNGILGLAT-UHFFFAOYSA-N 1-ethenyl-4-fluorobenzene Chemical group FC1=CC=C(C=C)C=C1 JWVTWJNGILGLAT-UHFFFAOYSA-N 0.000 description 1
• GNNDEPIMDAZHRQ-UHFFFAOYSA-N 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1(C(=O)NC=2C(=CC(OC=3C=C(NC(=O)C4CC4)N=CC=3)=C(F)C=2)F)CC1 GNNDEPIMDAZHRQ-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• HZTYDQRUAWIZRE-UHFFFAOYSA-N 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CN=C2NC(NC=2C(=CC=3CCN(C=3C=2)C(=O)CN(C)C)OC)=N1 HZTYDQRUAWIZRE-UHFFFAOYSA-N 0.000 description 1
• BCSHRERPHLTPEE-NRFANRHFSA-N 2-[[5-chloro-2-[[(6s)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5h-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=C3CCC[C@@H](CC3=CC=2)N2CCN(CCO)CC2)OC)=NC=C1Cl BCSHRERPHLTPEE-NRFANRHFSA-N 0.000 description 1
• FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 1
• LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
• APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• HEVHTYMYEMEBPX-HZPDHXFCSA-N 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C1=CC(OC[C@H](N)C)=CC=C1C1=CN=C2N1N=C(N[C@H](C)C=1C=C(F)C=CC=1)C=C2 HEVHTYMYEMEBPX-HZPDHXFCSA-N 0.000 description 1
• NVSHVYGIYPBTEZ-UHFFFAOYSA-N 4,5-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-3-carboxamide Chemical compound CC1=NNC(C(=O)NC=2C=C3C=C(NC3=NC=2)C=2C=CC=CC=2)=C1C NVSHVYGIYPBTEZ-UHFFFAOYSA-N 0.000 description 1
• CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 1
• QDPVYZNVVQQULH-UHFFFAOYSA-N 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 2-hydroxypropanoic acid hydrate Chemical compound O.CC(O)C(O)=O.C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 QDPVYZNVVQQULH-UHFFFAOYSA-N 0.000 description 1
• YLLPAAYZOKXPDB-UHFFFAOYSA-N 5-pyrimidin-2-yl-1h-pyrazol-4-amine Chemical class NC1=CNN=C1C1=NC=CC=N1 YLLPAAYZOKXPDB-UHFFFAOYSA-N 0.000 description 1
• PUIXMSRTTHLNKI-UHFFFAOYSA-N 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C=C)(=O)N1CCN(CC1)CCCN1C(C(=CC2=C1N=C(N=C2)NC)C2=C(C(=CC(=C2Cl)OC)OC)Cl)=O PUIXMSRTTHLNKI-UHFFFAOYSA-N 0.000 description 1
• RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
• GLYMPHUVMRFTFV-QLFBSQMISA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-[(3r,5s)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1C[C@H](C)N[C@H](C)C1 GLYMPHUVMRFTFV-QLFBSQMISA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• 229940126069 ALK kinase inhibitor Drugs 0.000 description 1
• GCYIGMXOIWJGBU-UHFFFAOYSA-N AZD3463 Chemical compound C=1C=C(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)C(OC)=CC=1N1CCC(N)CC1 GCYIGMXOIWJGBU-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 208000036652 Adenocarcinoma of the small intestine Diseases 0.000 description 1
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 206010071977 Anaplastic lymphoma kinase gene mutation Diseases 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• SIKYQMJEBRXCSM-UHFFFAOYSA-N COCC[S](N)CCOC Chemical compound COCC[S](N)CCOC SIKYQMJEBRXCSM-UHFFFAOYSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 229940124957 Cervarix Drugs 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108010041986 DNA Vaccines Proteins 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 229940124884 Engerix-B Drugs 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 229940032072 GVAX vaccine Drugs 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 229940124897 Gardasil Drugs 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010024405 HER2 peptide (369-377) Proteins 0.000 description 1
• 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
• 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
• 101000605496 Homo sapiens Kinesin light chain 1 Proteins 0.000 description 1
• 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 229940124672 IMA901 Drugs 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 108010078049 Interferon alpha-2 Proteins 0.000 description 1
• 102100040018 Interferon alpha-2 Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 102100038306 Kinesin light chain 1 Human genes 0.000 description 1
• 102100023422 Kinesin-1 heavy chain Human genes 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 230000037364 MAPK/ERK pathway Effects 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 102000005727 Mammaglobin A Human genes 0.000 description 1
• 108010031030 Mammaglobin A Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 208000010505 Nose Neoplasms Diseases 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229940029536 PANVAC Drugs 0.000 description 1
• 239000012270 PD-1 inhibitor Substances 0.000 description 1
• 239000012668 PD-1-inhibitor Substances 0.000 description 1
• 229940032310 PROSTVAC vaccine Drugs 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 1
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229940124908 Pediarix Drugs 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
• 201000008183 Pulmonary blastoma Diseases 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 229940124942 Recombivax HB Drugs 0.000 description 1
• 108700033496 Recombivax HB Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 101150077555 Ret gene Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 239000012317 TBTU Substances 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 229940096912 Trk tyrosine kinase inhibitor Drugs 0.000 description 1
• 229940124922 Twinrix Drugs 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• GJWAPAVRQYYSTK-UHFFFAOYSA-N [(dimethyl-$l^{3}-silanyl)amino]-dimethylsilicon Chemical compound C[Si](C)N[Si](C)C GJWAPAVRQYYSTK-UHFFFAOYSA-N 0.000 description 1
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
• IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000002454 adrenal cortex cancer Diseases 0.000 description 1
• 229960001686 afatinib Drugs 0.000 description 1
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
• 229960002833 aflibercept Drugs 0.000 description 1
• 108010081667 aflibercept Proteins 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 229960001611 alectinib Drugs 0.000 description 1
• KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
• 229950005952 altiratinib Drugs 0.000 description 1
• 229950001537 amatuximab Drugs 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229950006588 anetumab ravtansine Drugs 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 229960002594 arsenic trioxide Drugs 0.000 description 1
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
• 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
• 229960003852 atezolizumab Drugs 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
• 229950000971 baricitinib Drugs 0.000 description 1
• XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 229950003054 binimetinib Drugs 0.000 description 1
• ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 229940101815 blincyto Drugs 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229960000455 brentuximab vedotin Drugs 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 201000005242 bronchial neoplasm Diseases 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
• 229960001573 cabazitaxel Drugs 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 229950005852 capmatinib Drugs 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• NMMGUHANGUWNBN-OGLOGDKOSA-N cep-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 201000003719 cervical neuroblastoma Diseases 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 210000002726 cyst fluid Anatomy 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229940094732 darzalex Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 101150047356 dec-1 gene Proteins 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 229960002923 denileukin diftitox Drugs 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 238000007847 digital PCR Methods 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 229960001776 edrecolomab Drugs 0.000 description 1
• 229960004137 elotuzumab Drugs 0.000 description 1
• 229940038483 empliciti Drugs 0.000 description 1
• 208000023965 endometrium neoplasm Diseases 0.000 description 1
• 229950004126 ensartinib Drugs 0.000 description 1
• 229950000521 entrectinib Drugs 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 230000003090 exacerbative effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 229950002846 ficlatuzumab Drugs 0.000 description 1
• 229960004177 filgrastim Drugs 0.000 description 1
• MGZKYOAQVGSSGC-DLBZAZTESA-N fisogatinib Chemical compound COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1 MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 238000003682 fluorination reaction Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229950008692 foretinib Drugs 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 229950004003 fresolimumab Drugs 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 201000008361 ganglioneuroma Diseases 0.000 description 1
• 229950004896 ganitumab Drugs 0.000 description 1
• 229940102767 gardasil 9 Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
• 229950007540 glesatinib Drugs 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 201000010235 heart cancer Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 201000000284 histiocytoma Diseases 0.000 description 1
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960001507 ibrutinib Drugs 0.000 description 1
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 150000005233 imidazopyridazines Chemical group 0.000 description 1
• 229940091204 imlygic Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 238000011503 in vivo imaging Methods 0.000 description 1
• 231100000405 induce cancer Toxicity 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 229950007752 isatuximab Drugs 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229940045426 kymriah Drugs 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• 229950003970 larotrectinib Drugs 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 229950011263 lirilumab Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229950001290 lorlatinib Drugs 0.000 description 1
• IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
• 229950005069 luminespib Drugs 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000004880 lymph fluid Anatomy 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000012961 medicinal therapy Methods 0.000 description 1
• 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 229950009655 milciclib Drugs 0.000 description 1
• 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229940015637 mobocertinib Drugs 0.000 description 1
• 229950007699 mogamulizumab Drugs 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 1
• AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
• YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 208000037830 nasal cancer Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 229940029345 neupogen Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 230000007512 neuronal protection Effects 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 229950010203 nimotuzumab Drugs 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229960003347 obinutuzumab Drugs 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 229940100027 ontak Drugs 0.000 description 1
• 201000005443 oral cavity cancer Diseases 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229950007318 ozogamicin Drugs 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 229960002566 papillomavirus vaccine Drugs 0.000 description 1
• 208000007312 paraganglioma Diseases 0.000 description 1
• 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 229940121655 pd-1 inhibitor Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
• 229950010632 perifosine Drugs 0.000 description 1
• 229960002087 pertuzumab Drugs 0.000 description 1
• JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 201000002511 pituitary cancer Diseases 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000003476 primary myelofibrosis Diseases 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• AZSRSNUQCUDCGG-UHFFFAOYSA-N propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C AZSRSNUQCUDCGG-UHFFFAOYSA-N 0.000 description 1
• 229940034080 provenge Drugs 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 229960005562 radium-223 Drugs 0.000 description 1
• HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 229960004836 regorafenib Drugs 0.000 description 1
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
• 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
• FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229940018008 rilzabrutinib Drugs 0.000 description 1
• 229960005560 rindopepimut Drugs 0.000 description 1
• 229960000215 ruxolitinib Drugs 0.000 description 1
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
• HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 229950010746 selumetinib Drugs 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• 229950003647 semaxanib Drugs 0.000 description 1
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
• 238000011896 sensitive detection Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229960000714 sipuleucel-t Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000037969 squamous neck cancer Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 229950007866 tanespimycin Drugs 0.000 description 1
• AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940066453 tecentriq Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229940124788 therapeutic inhibitor Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229950007137 tisagenlecleucel Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 229960004066 trametinib Drugs 0.000 description 1
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 102000015533 trkA Receptor Human genes 0.000 description 1
• 108010064884 trkA Receptor Proteins 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 229950004593 ublituximab Drugs 0.000 description 1
• 229940022919 unituxin Drugs 0.000 description 1
• 229950005972 urelumab Drugs 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 229940126496 utatrectinib Drugs 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 108010069784 vitespin Proteins 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 229940014556 xgeva Drugs 0.000 description 1
• 229940055760 yervoy Drugs 0.000 description 1